Impact Of Taraxacum Officinale Silver Nanoparticle On Lipid Profile In Hyperlipidemia Rats

Hyperlipidemia is a significant modifiable risk factor for cardiovascular illnesses, which are still the main cause of death worldwide. In this work, rats with experimentally induced hyperlipidemia were used to test the therapeutic potential of biologically synthesized Taraxacum officinale silver nanoparticles (TOL-AgNPs). Taraxacum officinale leaf extract was employed in the production of the silver nanoparticles, which were subsequently analyzed by UV-Vis, FTIR, XRD, SEM, and EDX imagine. We randomly assigned thirty female Wistar albino rats (n = 6) to five groups: control group (normal diet), nanoparticle group (20 mg/kg TOL-AgNPs alone), hyperlipidemia group (cholesterol-enriched diet), antioxidant group (20 mg/kg TOL-AgNPs with cholesterol diet), and treated group received 2 weeks cholesterol-rich diet after that treated with 20 mg/kg TOL-AgNPs orally by gavage for four weeks .Upon evaluation of blood lipid profiles, liver function tests, oxidative stress biomarkers, kidney function tests, and histopathological investigations after 40 days, Low-density lipoprotein (LDL) and total cholesterol (TC) levels were found to be substantially reduced in the nanoparticle group than the hyperlipidemia group. Rats with hyperlipidemia had lower levels of high-density lipoprotein (HDL) than those that were treated (P < 0.05). Significant improvements were observed in liver function parameters, with ALT decreasing, AST, and ALP. Histopathological examination revealed complete prevention of hepatic steatosis, preservation of normal portal triads, and maintenance of sinusoidal architecture in TOL-AgNPs treated groups, contrasting with severe macrovesicular and microvesicular steatosis observed in hyperlipidemic controls.